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Abstract
The objective of this study is to assess the prevalence of psychiatric comorbidity in patients under treatment within the
addictive disorders assistance units of Galicia (Spain).
Material and Methods: A total of 64 healthcare professionals performed clinical diagnosis of mental disorders (on DSM IV-
TR criteria) in 2300 patients treated throughout March 2010 in 21 addictive disorders assistance units.
Results: 56.3% of patients with substance abuse/dependency also showed some other mental disorder, 42.2% of patients
suffering from at least an Axis I condition and 20.2% from some Axis II condition. Mood and anxiety disorders and borderline
and antisocial personality disorders were the most frequent disorders in both axes.
Conclusions: A high comorbidity was found between mental and substance use disorders (SUD) in patients seen at the
addictive disorders assistance units of Galicia.
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Introduction
Dual disorder is usually the term of choice used in describing the
co-occurrence of a substance use disorder (SUD) and another
mental disorder [1,2]. Although this association has been known
for 30 years, it was only in the last two decades that it has
increasingly become a source of interest largely because high
prevalence has been reported in the literature and the negative
influence such comorbidity may have on the evolution and
prognosis of both disorders [3].
This high prevalence found since the 1990s has been associated
to: the decrease in the number of long-term inpatients in
psychiatric hospitals where there was less access to toxic
substances; greater access (in both availability and price) to
substances of abuse (and particularly stimulants), improvement of
drug addiction assistance networks which has resulted in better
catchment and care of patients (and therefore of registered cases)
and an increase in diagnosis as professionals have a greater
understanding of this problem [3].
A number of studies report a high comorbidity between SUD
and mental disorders [4–8], with a highly variable prevalence as
studies have been conducted in heterogeneous populations
(clinical, prison, general populations) and using different method-
ologies.
Regier et al. (1990) [4] reported that 44% of alcohol abusers and
64.4% of illegal substance abusers that had started treatment for
drug use showed at least a major mental disorder while Kessler
et al. [5,6] found in a study of general population that persons
diagnosed with alcohol dependence were 4.1 times more likely to
suffer a mental disorder than non-alcohol dependent population
and that among persons with illegal drug dependency the risk was
4.9 times higher.
The prevalence of dual disorder is noticeably higher in
treatment samples than in community samples [9], as the latter
are not confined to persons requesting professional assistance
[4,10].
A particularly interesting study of clinical populations was
conducted in Canada by Rush & Koegl (2008) [11]. It comprised
9839 patients from different health programs from the system of
mental health services of the Ontario area and it found a global
prevalence for dual disorders of 18.5%, which could be more
representative of clinical reality.
The following variables have been associated with an increased
risk of suffering a dual disorder: male gender, young age, low
education, single, urban milieu and better premorbid level of
functioning, family history of substance abuse and a history of
traumatic life events [12].
Alcohol is the most frequent substance of abuse among dual
patients, followed by cannabis or cocaine, although the use of
amphetamines, opiates, hallucinogens, sedative agents, nicotine as
well as caffeine is also frequent. No psychopathology-related
preference has been reported, being substance availability the
determining factor for use [12].
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As to evolution and prognosis, patients with dual disorders have
a greater suicidal risk [11,13], greater use of ER visits and
psychiatric hospitalization as consequence of both a worsening of
symptoms as in the case of alcohol use in patients with affective
disorders and decreased treatment compliance [14,15], a worse
response to treatment with increased side effects and interactions
[16], a greater occurrence of violent behavior [17,18], greater
family instability and social exclusion [16,19,20], a greater
victimization risk [21], an increased risk of legal problems
[12,17], and a greater prevalence of communicable diseases
associated to risk-taking behaviors [22].
It should be borne in mind that among patients with major
psychiatric disorders and co-occurring substance abuse-related
problems, the prevalence of impulsive and antisocial behavior is
higher than among non-substance abuse psychiatric patients.
These behaviors accelerate the onset of both disorders, lead to the
use of multiple substances and therefore, result in increased
problems, more serious legal repercussions and decreased adap-
tation to the social, family and occupational environment [23].
Therapeutically, patients with dual diagnosis are both a
challenge and a dilemma for a healthcare system traditionally
organized into two parallel assistance services, one for mental
health and one dealing with addictions. Each healthcare service
tends to give treatment priority to the disorder that has
traditionally been within its scope while ignoring the other
disorder, thus making patient’s recuperation and improvement
less likely [3].
On the other hand, the effectiveness of existing programs and
interventions to treat dual disorders in a specific and comprehen-
sive manner has not been clearly proven [24]. Generally, the
different interventions may be applied in dual disorders. In other
words, the treatments that reduce psychiatric symptomatology also
work in dual patients and the same is true of treatments that
reduce substance abuse [25].
Another important methodological issue in our study is data
collection on toxic substance use, a greatly discussed factor in the
literature on dual disorders. Since studies indicate that over 50%
of patients are polydrug users, it does not seem viable to confine
studies to patients using only one toxic substance [26].
Indeed, Rounsaville et al. (2003) [27] suggested that a detailed
study should be conducted on the use of the different toxic
substances of abuse found in the environment so as to determine
which one was the main substance of abuse and consequently
focus attention on that substance. However, the determination of
which the main substance of abuse is has proved to be
heterogeneous as in some studies this term refers to the most used
substance while in others it refers to the substance that leads to the
greatest demand of treatment and finally others use the term to
speak of the substance that generates the greatest disability [26].
The use of structured and semi-structured interviews or
questionnaires to be filled out by patients and their relatives also
results in significant differences when measuring the main
substance of abuse [26].
Consequently, it is hardly surprising that dual disorders
represent a challenge not just for clinicians but also for healthcare
managers. In this regard, the main objective of this study was to
determine the prevalence of dual disorders in the addictive
disorders assistance units of Galicia (Spain).
Materials and Methods
This is a cross-sectional, descriptive and naturalistic study of
mental and substance use disorders (SUD) in patients seen at the
additive disorder assistance units of Galicia in the northwestern
region of Spain with a population of 2,797,653. The addictive
disorders assistance service comprises 17 drug dependency units
and 6 alcoholism units, where 84 healthcare professionals work (51
psychologists and 33 doctors).
Our definition of main substance was a substance that met the
following conditions: the most frequently used, the one leading to
treatment demand and greatest disability.
Sample
The study was conducted with all patients seen between the first
and the thirty first day of March 2010. This cross-sectional
strategy in a clinical population in which a sufficient period of
previous treatment and assessment is ensured has already been
used in other studies [11].
Protocols from 2560 patients were received, of which 260
(10.15%) were excluded as they did not comply with eligibility
criteria or were incomplete.
The final sample consisted of 2300 patients, 1834 (79.7%) were
male and 466 (20.3%) female. The mean age was 41.27 (SD:
10.13) (range: 18–64 years). All of them were being treated at the
addictive disorders assistance units of Galicia as they had problems
of abuse or dependence on one or several psychoactive substances.
Procedure
An ad hoc data collection protocol was written that included
sociodemographic variables, substances used (main and others)
and diagnosis of mental and use of substances disorders (DSM IV-
TR criteria) (APA, 2000) [28].
Protocols were filled out by 64 out of the 84 (76%) healthcare
professionals of the addictive disorders assistance units of Galicia.
Eligibility criteria were the capability to understand and sign
informed consent, age between 18 and 65 years and having been
treated for at least three months in the drug dependence or
alcoholism unit so that diagnoses were always based on a
longitudinal assessment made by expert professionals and on the
basis of all data available using the LEAD (longitudinal expert with
all data) method [20].
As it is frequent to find acute psychiatric symptomatology in
users of psychoactive substances without this implying that there is
basis for diagnosing a disorder, symptom persistence is necessary
for confirmation of that diagnosis [28].
Proper consideration must also be given to the presence of
behavioral changes in substance users from the states of
intoxication and abstinence which may be confused with
personality disorders. In this case persistence of alterations over
the time is needed to confirm its presence irrespective of episodes
of use and abstinence so as to ensure there is actually a personality
disorder [28].
The study was approved by the Ethical Committee of Clinical
Research of Galicia (Spain) (2010–011). All clinical investigation
has been conducted according to the principles expressed in the
Declaration of Helsinki. Participants provided their written
informed consent in all cases. All potential participants who
declined to participate or otherwise did not participate were
eligible for treatment (if applicable) and were not disadvantaged in
any other way by not participating in the study.Research was not
conducted outside of our country of residence. No current external
funding sources for this study.
Statistical Analysis
Statistical analysis was performed using Statistical package for
the social sciences for Windows-SPSS (version 15). For the
comparison of qualitative variables the chi-square test was used.
The level of statistical significance was set at p,0.05 for intergroup
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comparisons with the required post-hoc corrections when com-
parisons where made with the chi-square.
Multiple correspondence analysis was used for exploratory
analysis in order to identify association trends between the
explanatory variables and the results.
Results
Substance Abuse
The main substances of abuse reported in our sample were:
alcohol (42.5%), opiates (35%), cocaine (13%), cannabis (2.9%),
and other substances (2.2%). In 101 patients (4.3%) more than one
main substance was registered as none met the three, previously
defined requirements [26,27]; in this group of patients the most
frequent combination was the use of opiates and cocaine in 41
patients (40.6% of this group). Sociodemographic and substance
use variables are shown in table 1.
The different groups created as a function of the main substance
of abuse for statistical analysis were: the OP group (opiates), the
COC group (cocaine), the ALC group (alcohol) and the OS group
(other substances: cannabis, nicotine, psychoactive drugs or more
than one substance).
Taking into account the heterogeneity as regards the main
substance as well as the reduced size of the group OS, this group
was excluded for later intergroup comparisons.
63.9% of the sample was polydrug users. Polydrug use
frequency for each main substance was as follows: ALC (49.4%),
OP (79.1%) and COC (70%). In the ALC group the main
substances found in polydrug use were: cocaine (8.7% of total,
17.6% of polydrug use), cannabis (7.36% of total, 14.9% of
polydrug use) and opiates (1.02% of total, 2.07% of polydrug use);
in the OP group the main substances used in polydrug use were:
cocaine (43.1% of total, 54.4% of polydrug use), cannabis (30.7%
of total, 38.7% of polydrug use) and alcohol (19.2% of total, 24.3%
of polydrug use); Finally, in the COC group the main substances in
polydrug use were: Alcohol (41% of total, 52.11% of polydrug
use), cannabis (35% of total, 44.5% of polydrug use) and opiates
(13.3% of total, 17% of polydrug use).
Mental and Behavioral Disorders
Co-occurrence between mental disorders and SUD reached
56.3% of the total sample and 14.1% of patients showed more
than one mental disorder besides the addictive disorder.
The most prevalent diagnostic categories in the sample were
mood disorders (22.3%), personality disorders (20.5%) and anxiety
disorders (14.3%). The full list of diagnostic categories and of
mental disorders diagnosed is shown in Tables 2, 3 and 4.
Axis I Diagnoses
42.5% of the sample had Axis I disorders with significantly
lower presence in the OP group in relation to the other two groups
(Table 5).
The schizophrenia and psychotic disorders group (7.3%)
manifested mainly in the COC group, with significant differences
in relation to the OP and ALC groups. Of these, the substance-
induced psychotic disorder (2.9%) was significantly more frequent
in the COC group than in the other groups while schizophrenia
(2.1%) was significantly higher in the COC and OP groups in
comparison to the ALC group.
As to mood disorders, the main diagnoses were dysthymic
disorder (6.6%), substance-induced mood disorder (6.2%) and
major depressive disorder (4%), with no differences among groups
except for the substance-induced mood disorder, which was
significantly more frequent in the ALC group.
Among anxiety disorders (14.3%), substance induced anxiety
disorder (5.3%) and generalized anxiety disorder (2.8%) were the
most frequent, with a significantly higher presence of this latter
disorder in the COC group.
Table 1. Sociodemographic characteristics and main
substance of abuse.












Table 2. Prevalence of mental disorders; cognitive, psychotic
and mood disorders.
n %
Some diagnosis of mental disorder 1298 56.3
More than one diagnosis of a mental disorder 323 14.1
Some diagnosis of Axis I mental disorder 969 42.1
Some diagnosis of Axis II mental disorder 465 20.2





Schizophrenia and other psychotic disorders 169 7.3
Schizophrenia 48 2.1
Schizophreniform disorder 7 0.3
Schizoaffective disorder 7 0.3
Delusional disorder 19 0.8
Brief psychotic disorder 9 0.4
Substance-induced psychotic disorder 66 2.9
Psychotic disorder not otherwise specified 13 0.6
Mood disorders 511 22.2
Major depressive disorder 93 4
Dysthymic disorder 153 6.7
Manic episode 2 0.1
Hypomanic episode 4 0.2
Bipolar disorder 37 1.6
Cyclothymic disorder 14 0.6
Substance-induced mood disorder 141 6.1
Mood disorder not otherwise specified 67 2.9
doi:10.1371/journal.pone.0066451.t002
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Somatoform, dissociative and eating disorders (ED) affected a
small proportion of patients (0.8, 0.1 and 1.1% respectively). The
latter were significantly more frequent in the COC group.
Impulse-control disorders (ICD) not elsewhere classified (4.8%)
were significantly more frequent in cocaine users than in the
remaining groups, which was also true of ICD-not otherwise
specified.
Lastly, only 1.2% of patients in the sample displayed an
adjustment disorder.
The distribution of the more frequent different diagnostic and
mental disorder categories relative to the different groups of SUD
is displayed in table 5.
Axis II Diagnoses
20.2% of patients were diagnosed with some personality
disorder (PD). Such disorders were more frequent in the OP
group.
Particularly salient were Borderline Personality Disorder (BPD:
5.2%), Antisocial Personality Disorder (APD: 4.6%) and the
personality disorder not otherwise specified (4.3%). At the other
end of the scale, obsessive compulsive personality disorder (0.3%)
and avoidant personality disorder (0.3%) had the fewest diagnoses.
BPD was significantly more frequent in the OP and COC
groups in comparison to the ALC group while APD was strongly
associated to the OP group and personality disorder not otherwise
specified was associated to the ALC group.
The multiple correspondence analysis performed found that
substance of abuse groups are distributed separately into: COC
group, and OP and ALC groups (figure 1). Equally remarkable
was spatial distribution as cocaine abuse is at one extreme while
opiate and alcohol abuse is at the other extreme. As shown in
figure 1, the mental and behavioral disorders are all distributed
together and all of them very separated from substance abuse
groups. This is explained by the fact that only part of drug users
suffer from a mental and behavioral disorder and use is non-
related. Closeness of diagnostic categories to one use or the other is
in line with the prevalence each substance has as seen in the
descriptive analysis.
Discussion
The prevalence of mental disorders in the COPSIAD study
(56.3%) is close to that obtained in the Epidemiologic Catchment Area-
ECA study (60%) [4], and significantly lower than that of the
National Comorbidity Survey- NCS (78.3%) [29] and very similar to
that found in the NCS-R study (55%) [5,6], all of them baseline
studies in the field (although there were conducted in non-clinical
populations using different methodology).
The distribution for the most frequent mental disorders
obtained was similar to that reported in the pilot study by
Szerman et al. [8] in Madrid (Spain), although the prevalence of
dual disorder was significantly lower in the latter study, which also
included patients from the mental health network who tend to
present with dual disorder less frequently than patients seen in the
addictive disorders network.
A case in point is Rush & Koegl (2008) [11], where prevalence
of dual disorder varies depending on where within the mental
health system patients are assessed: 28% in hospitalized patients,
19.1% in intensive outpatient programs and 17.8% in regular
outpatient treatment.
Table 3. Prevalence of anxiety, somatoform, dissociative,
eating and impulse-control disorders.
n %
Anxiety disorders 330 14.3
Panic disorder 38 1.7
Agoraphobia 2 0.1
Specific phobia 1 0.05
Social phobia 10 0.4
Obsessive-compulsive disorder 15 0.7
Posttraumatic stress disorder 11 0.5
Acute stress disorder 6 0,3
Generalized anxiety disorder 64 2,8
Anxiety disorder due to general medical condition 12 0.5
Substance-induced anxiety disorder 123 5.3
Anxiety disorder not otherwise specified 48 2.1
Somatoform disorders 20 0.9
Somatization disorder 1 0.05
Conversion disorder 3 0.1
Pain disorder 5 0.2
Hypochondriasis 9 0.4
Undifferentiated somatoform disorder 2 0.1
Dissociative disorders 3 0.1
Dissociative amnesia 1 0.05
Dissociative amnesia disorder 2 0.1
Eating disorders 26 1,1
Anorexia nervosa 5 0.2
Bulimia nervosa 8 0.3
Eating disorder not otherwise specified 13 0.6
Impulse-control disorders not otherwise specified 117 5.1
Intermittent Explosive disorders 19 0.8
Kleptomania 2 0.1
Pathological gambling 28 1.2
Impulse-control disorders not otherwise specified 68 3
doi:10.1371/journal.pone.0066451.t003
Table 4. Prevalence of adjustment and personality disorders.
n %
Adjustment disorder 39 1,7
Personality disorder 465 20.2
Paranoid personality disorder 31 1.3
Schizoid personality disorder 17 0.7
Schizotypal personality disorder 9 0.4
Histrionic personality disorder 33 1.4
Borderline personality disorder 119 5.2
Antisocial personality disorder 106 4.6
Narcissistic personality disorder 11 0.5
Obsessive-Compulsive personality disorder 6 0.3
Avoidant personality disorder 7 0.3
Dependent personality disorder 26 1.1
Personality disorder not otherwise specified 100 4.3
doi:10.1371/journal.pone.0066451.t004
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A common finding in many studies is the close association
between cocaine use and the presence of mental disorders
[4,7,8,29].
In our study, the presence of Axis I mental disorders was
significantly lower in the OP group than in the COC and ALC
groups. In all three groups there was a predominance of mood
disorders, which coincides with the NCS [29] and was also largely
consistent with percentages in the ECA groups, with the exception
of alcohol users who were more frequently diagnosed with anxiety
disorders [4]; in the NCS-R anxiety disorders were also more
frequent [5,6].
Mood disorders (22.3%) were more frequent in the ALC group
(24%), with a significant association between substance-induced
mood disorder and alcohol use. The association between affective
disorders and alcohol use was been reported in many previous
studies: as many as 45% of patients with a diagnosis of alcohol
dependency satisfy the criteria of major depression. Nonetheless,
after 4 weeks of abstinence, the percentage decreases to 6%. On
the other hand, alcohol-abstinent patients are four times more
likely to develop a depressive disorder. Furthermore, the efficacy of
the antidepressant treatment is decreased if there is alcohol use
involved [30].
It might be that the serotonergic depletion caused by chronic
alcohol abuse accounts for these findings [30]. The low level of
polydrug use of the ACL patients in our study confirms this special
association between depression and chronic alcohol abuse.
Anxiety disorders were also frequent, with a significant
association between these disorders and the COC group. The
increase in noradrenergic activity at the locus coeruleus, typical of
stimulating agents such as cocaine would worsen anxiety
symptoms [30].
Like other authors [8], we found a predominance of psychotic
disorders in the COC group, particularly relevant in substance-
induced psychotic disorders, which seems reasonable as psychosis
is one of the most common complications of cocaine use.
It is estimated that up to 68% of cocaine addicts display abuse-
related psychotic manifestations [31]. Cocaine’s ability to block up
to 77% of dopamine reuptake would account for the appearance
of these disorders [30]. These psychotic symptoms may persist for
months after cocaine use has stopped or even become chronic.
Another diagnostic category with an unexpectedly high
prevalence was impulse control disorders (ICD) not elsewhere
classified. Their frequency was significantly higher in the COC
group. This seems only reasonable as this substance may alter the
inhibiting ability of the prefrontal cortex and increase the limbic
emotional response which may lead to the manifestation of
impulsive behaviors [30].
On the other hand, the relatively high presence of ICDs not
otherwise specified (3%) coupled with the inexistence of a
substance-induced ICD diagnosis in the DSM IV-TR, may lead
us to think that the impulsivity ‘‘trait’’ and the impulsivity ‘‘state’’
are being intermingled, notably in the COC group (5.3%).
Eating disorders (ED) were significantly more frequent in the
COC group. In this regard, it was been found that the greater the
severity of the ED, the higher is the number of the substances
abused [32], which may account for the results obtained although
their low prevalence (1.1%) precludes drawing any conclusion on
the matter.
Table 5. Diagnostic categories and most frequent diagnoses per groups.
1. Opiates
N = 805 n (%)
2. Cocaine
N = 300 n (%)
3. Alcohol




Delirium, dementia, amnestic and other cognitive disorders – 1(0.3) 5(0.5) 4.04
Schizophrenia and other psychotic disorders 61(7.6) 38(12.7) 46(4.7) 23.24*** 1–2, 1–3, 2–3
Schizophrenia 23(2.9) 6(2) 11(1.1) 7.04* 1–3, 2–3
Substance- induced disorder 22(2.7) 21(7) 18(1.8) 21.67*** 1–2, 2–3
Mood disorders 166(20.6) 55(18.3) 235(24) 5.59
Major depressive disorder 25(3.1) 13(4.3) 49(5) 4.02
Dysthymic disorder 59(7.3) 15(5) 64(6.5) 1.93
Substance-induced mood disorder 35(4.3) 10(3.3) 84(8.6) 18.60*** 1–3, 2–3
Anxiety disorder 96(11.9) 53(17.7) 147(15) 6.92*** 1–2, 1–3
Generalized anxiety disorder 17(2.1) 18(6) 24(2.5) 12.96** 1–2, 2–3
Substance-induced anxiety disorder 32(4) 19(6.3) 62(6.3) 5.37
Somatoform disorders 10(1.2) 3(1) 5(0.5) 2.93
Eating disorders 4(0.5) 8(2.7) 8(0.8) 11.21** 1–2, 1–3, 2–3
Impulse control disorders not elsewhere classified 24(3) 23(7.7) 43(4.4) 11.63** 1–2, 2–3
Impulse control disorders not otherwise specified 18(2.2) 16(5.3) 19(1.9) 1114** 1–2, 2–3
Personality disorder 213(26.5) 50(16.7) 155(15.8) 35.27*** 1–2, 1–3
Borderline personality disorder 57(7.1) 21(7) 32(3.3) 14.87*** 1–3, 2–3
Antisocial personality disorder 74(9.2) 6(2) 16(1.6) 62.76*** 1–2, 1–3
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On the other hand, the comorbidity obtained in our study in
Axis II (20.5%) is quite below that reported by other authors
[33,34]. This may be due to a variety of causes such as:
a) the use of psychometric instruments in some studies [33,34],
which could possibly increase the number of Axis II
diagnoses. Indeed, in some studies a single individual is
diagnosed with several different personality disorders [33,34],
which can hardly be accepted from a clinical point of view.
b) time of assessment: our study only includes patients with a
follow-up of at least 3 months so as to maximally reduce the
number of patients who might be under the effect of
substance intoxication or withdrawal, which might contribute
to explain the psychopathological symptoms attributable to
these contexts as an part of an independent mental disorder.
Contrary to what we saw in the case of Axis I, we find a higher
comorbidity for Axis II disorders for all groups of non-alcoholic
substances (OP: 26.5%, COC; 16.7%) than in the alcohol group
(ALC: 15.8%), although the difference is only significant for the
OP group. This had already been reported in earlier studies such
as NESARC [35].
The most frequent personality disorders (PD) were borderline-
BPD (5.3%) – considered as the most prevalent personality
disorder among substance abusers [36], and the antisocial-APD
(4.6%) and PD not otherwise specified (4.3%). The high
prevalence of BPD and APD reported among substance abusers
may be associated to impulsivity (common to both disorders)
whose role as vulnerability factor for addiction development has
been widely acknowledged [37].
These results are similar to those reported by Barea et al. [33],
although this latter study yields higher prevalences (BPD: 17.4%;
PD not otherwise specified: 14.3%; APD: 12.6%), probably
because of the type of population targeted in the study (mainly
opiates users) and the method of diagnosis (IPDE- International
Personality Disorder Examination).
Much higher prevalences were found in the ATOS study [34],
conducted on a sample of 615 heroin users, where 71% of patients
were diagnosed with APD, 46% with BPD and 38% satisfied the
criteria for both disorders.
We believe that the lower prevalence of PD found in our study
may be attributable to the preeminent role given to clinical
diagnosis.
Obviously, conclusions are applicable to the outpatient popu-
lation seen at addictive disorders units, and may not be generalized
to the universe of substance abusers. In this regard, the seriousness
of dual disorder increases as we get closer to specialized services,
among other things because patients with more than one
psychiatric disorder are more likely to demand specialized
assistance [38,39].
Graphical representation of correspondence analysis indicates
that there are two major groups of users: cocaine users on the one
hand and opiates and alcohol on the other. The mental and
behavior disorders are not clearly associated to a specific substance
abuse group. All mental and behavior disorders are grouped close
together but far from substance abuse groups. The reason for this
is that in this sample the diagnosis of substance abuse is central for
Figure 1. Multiple correspondence analysis of mental disorders and substance abuse.
doi:10.1371/journal.pone.0066451.g001
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sample collection. Particularly remarkable is the fact that in the
results obtained opiates and alcohol groups go together while the
cocaine group stands alone. This would indicate different patterns
in substance abuse as shown clearly in the descriptive analysis.
In summary, our study indicates the presence of a high
prevalence of mental disorders in a clinical population of patients
seen in addictive disorders units. High polydrug use, particularly in
the case of the OP and COC groups, together with a high
presence of substance-induced Axis I disorders, and whose
association to use groups is clearly physiopathologically based
(depression to alcohol, psychosis and impulsivity to cocaine) seem
to confirm the absence of a clear tendency towards the abuse of a
given substance on the basis of a previous psychopathology [40].
As to Axis II disorders, the high use of cocaine in patients from
the OP group does not allow us to state that impulsivity and
emotional instability predispose to a greater use of opiates.
Furthermore, there are no significant difference in the BPD
between the OP and the COC groups and it is highly likely that
the higher number of criminal behaviors associated to the abuse of
inhaled and injected substances increases the diagnosis of
antisocial PD [40] in the OP group.
The main strengths of this study are its sample size and the use
of DSM IV-TR diagnostic criteria that allow for discrimination
between ‘‘primary disorders’’ and ‘‘substance-induced disorders’’
[28].
A potential limitation of this study is the absence of structured
interviews to diagnose mental disorders in this type of populations
such as the Psychiatric Research Interview for Substance and
Mental Disorders (PRISM) [41], although we are of the opinion
that the fact that longitudinal diagnoses are made by the patient’s
clinicians is an added value.
Other limitations were: the inclusion of cases in each unit,
which was not uniformly done, and might have had implications
on the sample collection procedure; no data on the evolution of
toxic substance use was collected and no temporal sequencing was
established regarding the onset of disorders.
Bearing all these factors in mind, we believe that the important
sample size (n = 2300) provides us with valuable information on
the reality found in the addictive disorders units of Galicia.
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Ana Marı́a González, Psychiatrist, Drug Dependency Unit, Santiago de
Compostela, (Spain); Ana Marı́a Inés Queijeiro, General Practitioner,
Alcoholism Unit, A Coruña (Spain); Ana Marı́a Fernández, Psychiatrist,
Drug Dependency Unit, Monforte de Lemos (Spain);Andrés Fontenla,
Psychiatrist, Drug Dependency Unit, Cangas (Spain); Avelina Senra,
Psychologist, Drug Dependency Unit, Pontevedra (Spain); Berta Gómez,
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19. Baena MR., LópezJ (2006): Trastornos duales, mecanismos etiopatogénicos.
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